<table>
<thead>
<tr>
<th>Basic Science</th>
<th>Rehabilitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognition, Depression, and Psychosocial</td>
<td>Symptom Management</td>
</tr>
<tr>
<td>Disease Management, Mechanisms, and Treatment</td>
<td></td>
</tr>
</tbody>
</table>

*Note: The posters might take a while to load because of the file size.*

### Basic Science

| SC01 | Use of Accelerometers to Measure Real-Life Physical Activity in Ambulatory MS Individuals of Different Disability Levels, poster |
| SC02 | Brain Structural And Functional Abnormalities in Multiple Sclerosis, poster |
| SC03 | A Comparison of XP23839 with DMF, the Active Ingredient of BG-12, poster |
| SC04 | The Critical Role of the Toll Like Receptor 2/Myeloid Differentiation Primary Response Gene (88) Pathway in Danger Signaling and Failure of Myelin Regeneration, poster |
| SC05 | How Are Relapses, Symptoms and Disease Progression Linked in Early Multiple Sclerosis?, poster |
| SC06 | Migraine is Comorbid with Multiple Sclerosis in Nationwide Inpatient Sample, poster |
| SC07 | Characterizing Benign Multiple Sclerosis Using Age, Disease Duration and Impairment, poster |
| SC08 | Costimulatory Molecule CD40 is Elevated in Patients with MS, poster |

### Cognition, Depression, and Psychosocial

| CG01 | Social Workers Collaborate to Improve Care for Veterans with MS, poster |
| CG02 | The MS Social Workers Collaborative of Washington: Sustainable and Thriving, poster |
| CG03 | Can Demyelinative Lesion in the Brain Cause Behavioral Change? |
| CG04 | Self-Efficacy Improvement in Multiple Sclerosis (SIMS): A Pilot Study, poster |
| CG05 | An Update on Physical Activity and Cognition in Persons with MS, poster |
| CG06 | Optical Coherence Tomography Metrics and Third Ventricular Width are Associated with Costimulatory Molecules in Multiple Sclerosis, poster |
| CG07 | The Experiences of Mothers with Multiple Sclerosis, poster |
| CG08 | Prism: A Novel Research Tool to Determine Prevalence of Pseudobulbar Affect, poster |
| CG09 | A Mother’s Love, Multiple Sclerosis & the Correlation Between Flare Incidence and Sibling’s Quality of Life, poster |
| CG10 | Multiple Sclerosis Presenting as a Focal Cognitive Syndrome, poster |
| CG11 | Characteristics of Depression Disorders in Multiple Sclerosis, poster |
| CG12 | A Study to Identify the Psychosocial Needs of Caregivers of Persons with MS, poster |
| CG13 | The Soul Therapy, poster |
| CG14 | Computer Practice and Cognitive Functioning in Multiple Sclerosis, poster |
| CG15 | Cognitive Dysfunction in MS: Education Translates Science Into Practice, poster |
| CG16 | Subtypes of Depression in Multiple Sclerosis: Phase 1 - Best Evidence Synthesis and Epidemiological Prognosis Framework, poster |
| CG17 | Addressing the Challenges Faced by Family Caregivers of People with MS, poster |
| CG18 | Effectiveness of a Psychoeducational Wellness Program in Multiple Sclerosis, poster |
| CG19 | Health-Related Quality of Life Among People with MS and Urinary Symptoms, poster |
| CG20 | Productivity Impairment Among People with MS and Urinary Symptoms, poster |
| CG21 | The Relationship Between Pain and Depression in MS, poster |
| CG22 | Cognitive Reserve as a Possible Predictor of Cognitive Impairment in People with Multiple Sclerosis, poster |
| CG23 | Nursing and Social Work Collaboration: Pioneering Patient Centered Care for MS, poster |
2012 CMSC Posters
Written by Rachelle Ramirez - Last Updated Thursday, 17 December 2015 16:49

CG24 Negative Feelings Due Multiple Sclerosis in Caregivers and Patients
CG25 Quality of Life in Caregivers of Elderly Patients with MS
CG26 The 'Long Duration' Multiple Sclerosis Patient: No One Gets Away That Easy
CG27 A Pilot Interdisciplinary Group Cognitive Rehab Intervention for MS: 1-Year Follow-Up
CG28 The Effect of a Creative Art Program on Individuals with Multiple Sclerosis,
CG29 MS Depression Screening to Increase Physical Activity and Improve Mental Health
CG30 InMotion: A Phone-Based RCT to Increase Physical Activity and Improve Motor and Neurocognitive Functioning in a Sample of Veterans with Multiple Sclerosis
CG31 The Addition of Biofeedback and Mindfulness Based Training Components to a Psychoeducational Model for a Multiple Sclerosis Support Group

Disease Management, Mechanisms, and Treatment
DX01 Benefit/Risk Evaluation of Multiple Sclerosis Treatments by Patients and Physicians
DX02 Changes in Disability Status in Beta-Interferon Treated Multiple Sclerosis Patients
DX03 What Prompts a Switch to Disease Modifying Therapy Beyond First Line Therapy
DX04 Hospitalizations Among Patients with Multiple Sclerosis
DX05 Challenging Management of Neuromyelitis Optica During Pregnancy
DX06 Clinical Outcomes and Cause of Death in Patients From the 21-Year Long-Term Follow Up Published Study
DX07 Interactive Multiple Sclerosis Self-Paced Nurse Education Program
DX08 Fingolimod Efficacy by Prior Disease-Modifying Therapy Experience: FREEDOMS
DX09 Patient Preferences for Multiple Sclerosis Treatments: TRIBUNE Study
DX10 Interferon Beta-1A Titration Reduces Subjective Flu-Like Symptoms and Fever
DX11 Subcutaneous Interferon Beta-1A Treatment of Pediatric Multiple Sclerosis
DX12 The Multiple Sclerosis Self-Management Workshop
DX13 Rituximab Therapy in Secondary-Progressive Multiple Sclerosis: A Two-Year Longitudinal Observation of a Real World Setting
DX14 Analysis of First Dose Observation Data for MS Treatment with Fingolimod,}
DX15 The History of the Vascular Theories of Multiple Sclerosis
DX16 Clinical Aspects of Multiple Sclerosis Patients with Normal Spinal Cord Imaging
DX17 Incidence of Silent Spinal Cord Lesions in Relapsing Remitting Multiple Sclerosis
DX18 T-Cell Subtype in Multiple Sclerosis Patients Treated with Fingolimod
DX19 The Food Critic Who Couldn’t Taste and 6 Other Cases of Dysgeusia in Multiple Sclerosis
DX20 Pseudobulbar Affect in MS: Baseline Interrelations in a Study Cohort
DX21 Effects of BG-12 on Magnetic Resonance Imaging Outcomes in the DEFINE Study
DX22 Case Report: Progressive Encephalopathy in a Multiple Sclerosis Patient Receiving Tysabri
DX23 High Risk Syndrome for Neuromyelitis Optica: A Clinical Analysis and Follow-Up Study
DX24 Association of Neurologic Deficits: Manual Injection vs. Autoinjector Use
DX25 Patient Injection Setting Preferences on an Autoinjector for IFN β-1A
DX26 As Observational Study Examining Factors Affecting Quality of Life in Subjects Taking Dacarbazina HYP Improves Quality of Life in Multiple Sclerosis Patients
DX27 Fingolimod Slows Brain Volumetric Loss Regardless of Inflammatory Activity
DX28 Identifying the Needs of Women With Relapsing Remitting MS of Childbearing Age
DX29 Multiple Sclerosis and Huntington's Chorea: a Case Report and Literature Review
DX30 Strive Study: Natalizumab in Anti-JCV Seronegative Patients With Early MS
DX31 Safety and Tolerability of BG-12 in the Phase 3 CONFIRM Study
DX32 Strive Study: Natalizumab in Anti-JCV Seronegative Patients With Early MS
DX33 Quantifying Neurodegeneration in Multiple Sclerosis White Matter Tracts With Diffusion Tensor Imaging
DX34 Cost Sharing and Initiating Disease-Modifying-Therapy for MS.
DX35 You Are What You Walk: Investigating the Clinical Meaningfulness of the Timed 25 Foot Walk (T25FW),
DX36 Neuromyelitis Optica (NMO) Diagnosed As Syrinx On MRI,
DX37 Establishing a Gilenya Service in Greater Manchester (UK),
DX38 Observations of Patients With Multiple Sclerosis Reporting Endovascular Procedures,
DX39 Misdiagnosis of Initial Neurological Symptoms As Vascular Disease Rather Than Demyelinating Disease,
DX40 Alemtuzumab Improves Quality of Life Compared To IFNB-1A in CARE-MS I,
DX41 Alemtuzumab-Associated Infusion Reactions in CARE-MS I,
DX42 Observations On the Design of Secondary Progressive MS Trials,
DX43 Utilization of Shared Medical Appointment for First Day Observation for Fingolimod,
DX44 A Novel Method of Sharing Practice Patterns: the Mellen Center “Approach”
DX45 Fingolimod Efficacy by Time Since First Symptoms in Phase 3 Studies,
DX46 Patient-Reported Outcomes After Switching To Fingolimod: EPOC Study Design
DX47 Effect of Fingolimod On the Immune Response To Vaccination,
DX48 How To Improve Patient-Centered Care With Increased Cost Effectiveness,
DX49 Atypical Multiple Sclerosis With Bilateral Internal Jugular Vein Occlusion,
DX50 Multiple Sclerosis After Bariatric Surgery,
DX51 Hospital and ER Use Among Newly Diagnosed Multiple Sclerosis Patients,
DX52 Multiple Sclerosis Patient Treated With Natalizumab Develops Immune Thrombocytopenic Purpura,
DX53 The Gulf War Era Multiple Sclerosis Cohort: Clinical Features At First Diagnosis
DX54 Rebound Symptoms in Clinically Isolated Syndrome (CIS) Or Multiple Sclerosis,
DX55 NARCOMS: Simple Observation of Relapses Perceived To Be Inferior To Therapy,
DX56 Vitamin D Status in African-American Patients With Multiple Sclerosis: a Cohort Study
DX57 Cost Effectiveness of Early Versus Delayed Treatment With Fingolimod,
DX58 High Dose Immunosuppressive Therapy (HDIT) With Autologous Hematopoietic Stem Cell Transplantation (HSCT) Is Effective in Multi-Agent Refractory Neuromyelitis Optica (NMO),
DX59 A One-Year Analysis of Fingolimod Utilization Patterns in Multiple Sclerosis Patients
DX60 Pegylated Interferon Beta-1a in Relapsing MS: Baseline Characteristics,
DX61 Phase 2 Study of Fingolimod Efficacy and Safety in Japanese Patients,
DX62 Correlation Between Quality of Life and Clinical and MRI Measures in Early MS,
DX63 Physical and Mental Comorbidities in a Managed Care Population With Multiple Sclerosis,
DX64 Impact of Comorbidities On Medical Costs in Health Plan Members With Multiple Sclerosis,
DX65 Daclizumab HYP Reduces Multiple Sclerosis Clinical Disease Activity,
DX66 Adrenocorticotropic Hormone Treatment of Multiple Sclerosis Exacerbations
DX67 Clinical Importance of Accelerometer Output in Multiple Sclerosis,
DX68 Consistent Efficacy of Fingolimod Across Clinical Development Program
DX69 Pregnancy, Alphafetoprotein and MS,
DX70 Predictors of Medication Adherence To Fingolimod: An Analysis of Specially
DX71 Anti-JCV Antibody Status of MS Patients: Baseline Results of STRATIFY-2,
DX72 Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
DX73 Final Results From the Intramuscular Interferon Beta-1A Pregnancy Registry
DX74 Safety and Pharmacokinetics of BG-12 Given With and Without Aspirin,
DX75 CCSVI: the Message in Social Media,
DX76 Does Risk Tolerance To MS Therapies Change Over Time? a NARCOMS Survey
DX77 Effects of BG-12 On Quality of Life in Relapsing-Remitting MS in DEFINE,
DX78 The Modified Rankin Score Compared To EDSS and MRI Measures in the OLINDA
DX79 Sustained Long Term Use of Interferon Beta-1A in Patients With Relapsing
2012 CMSC Posters

Written by Rachelle Ramirez - Last Updated Thursday, 17 December 2015 16:49

DX80  Longitudinal Follow Up of a Cohort of Subjects With Incidental Abnormal MRI
DX81  Total Macular Volume and Its Association With Ambulatory Parameters in Patients With Cognitive Impairment Maintain Good Treatment Adherence With Clinical and Demographic Features of Participants in a VA Longitudinal Study
DX82  The Pacific Northwest MS Registry: Year 4 Update and Diagnosis Validation
DX83  Comparing Rituximab Induction Followed by Glatiramer Acetate To Glatiramer Acetate Alone in Patients With Cognitive Impairment Maintain Good Treatment Adherence With Clinical and Demographic Features of Participants in a VA Longitudinal Study
DX84  An Open-Label, Survey-Based, Multicenter Study To Determine Patient Satisfaction With the Use of Single-Use Prefilled Avonex® Pen Autoinjector
DX85  Patients With Cognitive Impairment Maintain Good Treatment Adherence With Clinical and Demographic Features of Participants in a VA Longitudinal Study

Rehabilitation
RH01  Mentally Simulated Motor Actions in Neurorehabilitation: A New Protocol for Rehabilitation
RH02  Effects of a Physical Therapy Reference for Neurologists Treating Multiple Sclerosis
RH03  Physical Therapy, A Part of a Multidisciplinary Team for People with Multiple Sclerosis
RH04  Comparison of Actigraphy and accelerometers in Persons with MS and Healthy Controls
RH05  Two Conditions of Administering the Six-Minute Walk in Persons with MS, The Pacific Northwest MS Registry: Year 4 Update and Diagnosis Validation
RH06  Effects of a Fall Prevention Initiative on Falls During Outpatient Visits in an MS Clinic
RH07  The Effects of a 6-Minute Endurance Walk on Selected Gait Characteristics
RH08  Newly Diagnosed Clinic: Emerging Model in MS Care
RH09  Activity Based Rehabilitation May Preserve Function in Multiple Sclerosis
RH10  Impact of a Hip Flexion Assist Device on Gait Performance in MS
RH11  Agreement Between Self-Report and Clinician-Administered EDSS Scores
RH12  Validity and Sensitivity of Spatiotemporal Parameters of Gait in MS
RH13  People with Multiple Sclerosis Show Improved Gait with Balance-Based Training
RH14  Berg Balance Scale Scores in Persons with Multiple Sclerosis are Different in Fatigued vs. Non-Fatigued Conditions
RH15  Validation of Self-Reported Balance and Mobility Measures in MS
RH16  Validation of an Abbreviated Activities-Specific Balance Confidence Scale in MS
RH17  Walking Impairment and Gait Variability in Multiple Sclerosis
RH18  Whole Limb Vibration Facilitates Magnetic Evoked Potential (MEP) Responses
RH19  Targeted Lower Extremity Training Effects on Gait Abnormalities
RH20  Evaluation of a Multiple Sclerosis Educational Track for Physical Therapy Students
RH21  Associations Between a Measurement of Upper Limb Function and the Expanded Disability Status Scale in Multiple Sclerosis
RH22  Qualitative Needs Assessment of People with Multiple Sclerosis
RH23  Employment Needs of People with Multiple Sclerosis
RH24  Psychometric Properties of Three Depression Scales in People with Multiple Sclerosis
RH26  Weight Status and Disability in Multiple Sclerosis
RH27  Multiple Sclerosis Walking Scale-12 Scores and Gait Parameters
RH28  Neurotronics Walkaide in MS Patients
RH29  Predicting Community Participation in Adults with Multiple Sclerosis
RH30  Dual Task Mobility and Falls Risk in Persons with Multiple Sclerosis
RH31  The Path to Work in People with Multiple Sclerosis
RH32  Tracking Instrumented Gait and Balance in Multiple Sclerosis Over 18 Months
RH33  The Effects of Strength Training Protocols on Fatigue, Strength and Quality of Life In Persons with Multiple Sclerosis
RH34  Physical Activity, Self-Efficacy, and Health-Related Quality of Life In Persons with Multiple Sclerosis
RH35  A Comparison of Balance Training in Multiple Sclerosis: Conventional Training
Symptom Management

SX01  Dose-Finding Study of Dextromethorphan/Quinidine for Central Neuropathic Pain in Multiple Sclerosis
SX02  Evaluation of Provider Referrals to Additional Services for Management of Multiple Sclerosis
SX03  Assessing Quality Measures in Multiple Sclerosis Patients with Initiation of Dalfampridine and Mobility in Multiple Sclerosis: Beyond the 25-Foot Walk Test
SX04  Fatigue: Take Control: A Multi-Center Randomized Controlled Trial
SX05  Walking Speed and Health-Related Quality of Life in Multiple Sclerosis
SX06  Correlation of Functional Impact of Headaches in an MS Cohort
SX07  Disease Modifying Treatments and Multiple Sclerosis Symptoms
SX08  Office-Based Single-Bolus Intrathecal Baclofen Trials in MS Patients: A Call to Action
SX09  Gilenya® Risk and Support Program (GRASP): A Melbourne Experience
SX10  Participation in Multiple Sclerosis Wellness Programs and Services
SX11  Features in Spontaneous Speech and Conversational Narrative: Comparison to Normal Speech
SX12  There's More Hidden Below the Belt Than First Thought
SX13  Treatment Consensus for Flu Like Symptoms During Interferon Therapy for Multiple Sclerosis
SX14  Ampyra Improves Walking and Community Participation in Veterans with Multiple Sclerosis
SX15  Demographic Assessment of Dalfampridine Extended Release Tablets Usage
SX16  Patient or Caregiver Knowledge of Dalfampridine Safety and Use Information
SX17  Prescriber Utilization Study of Dalfampridine Extended Release Tablets
SX18  The Impact of Tobacco Use on Symptoms in Persons with Multiple Sclerosis
SX19  Town Hall Discussions: Information, Support, Growth and Development of Multiple Sclerosis Nurses During Moderated Dialogues
SX20  The Prevalence of Asymptomatic Urinary Tract Infections in Persons with Multiple Sclerosis
SX21  Neuromyelitis Optica is Frequently Associated with Severe and Intractable Pain
SX22  Multiple Sclerosis and Spinal Cord Care: Expanding Access and Coordination
SX23  Symptomatic Correlates of Six-Minute Walk Performance in Persons with Multiple Sclerosis
SX24  Migraines in Multiple Sclerosis: Reports from a Multiethnic Cohort
SX25  Symptom Management